We showed that, among the current core plasma biomarkers, a combination of plasma P‐tau, GFAP, and NfL is informative for clinically relevant questions: (early) AD, FTD, or DLB (differential) diagnosis. The gene discussed is MAPT; the disease is Alzheimer disease.